Early and long term anamnestic response to HBV booster dose among fully vaccinated Egyptian children during infancy

Vaccine

Volumn 36, Issue 15, 2018, Pages 2005-2011

  Salama, Iman I ^a   Sami, Samia M ^a   Said, Zeinab N ^b   Salama, Somaia I ^a   Rabah, Thanaa M ^a   Abdel Latif, Ghada A ^a   Elmosalami, Dalia M ^a   Saleh, Rehan M ^a   Abdel Mohsin, Aida M ^a   Metwally, Ammal M ^a   Hassanin, Amal I ^a   Emam, Hanaa M ^a   Hemida, Samia A ^a   Elserougy, Safaa M ^a   Shaaban, Fatma A ^a   Fouad, Walaa A ^a   Mohsen, Amira ^a   El Sayed, Manal H ^c  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b AL AZHAR UNIVERSITY   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Anamnestic response; HBs antibodies; HBsAg; HBV vaccine

Indexed keywords

EUVAX; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B ANTIBODY;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; EGYPTIAN; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INFANT; MALE; PEDIATRICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; RURAL AREA; VACCINATION; BLOOD; EGYPT; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; NEWBORN; PRESCHOOL CHILD; SECONDARY IMMUNIZATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; EGYPT; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFANT; INFANT, NEWBORN; MALE; VACCINATION;

EID: 85043355895     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2018.02.103     Document Type: Article

References (42)

1. World Health Organization, Global Hepatitis Report; 2017 Available at: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ [Accessed 5 November 2017].
2. Egypt Health Issues Survey. Ministry of Health and population Cairo Egypt. El-Zanaty and associates Cairo Egypt. The Dhs Program ICF International, Rockville, Maryland, USA; 2015. Available at: https://dhsprogram.com/pubs/pdf/FR302/FR302.pdf [Accessed 9 June 2017].
3. World Health Organization, Global Programme for Vaccines and Immunization, Strategic Plan 1998–2001 Available at: http://www.who.int/iris/handle/10665/65204 [Accessed 12 November 2017].
4. Van Damme, P., Kane, M., Meheus, A., Integration of hepatitis B vaccination into national immunization programmes. BMJ 314 (1997), 1033–1036.
5. World Health Organization, Weekly Epidemiol Rec 92 (2017), 369–392.
6. Watson, B., West, D.J., Chilkatowsky, A., Piercy, S., Ioli, V.A., Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine 19 (2001), 3164–3168.
7. Gilca V, De Serres G, Boulianne N, De Wals P, Murphy D, Trudeau G et al. Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine. Human Vaccines 6:1, 212–218; February 2010; © 2010 Landes Bioscience.
8. Plotkin SA, Orenstein WA, Offit PA. Vaccines. 5th ed. A.P.a.W.A.O. Stanley. Philadelphia: Saunders Elsevier; 2008. p. 1725.
9. European, Consensus Group, Consensus statement: are booster immunizations needed for lifelong hepatitis B immunity?. Lancet 355 (2000), 561–565.
10. Wang, L.Y., Lin, H.H., Ethnicity, substance use, and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. J Hepatol 46 (2007), 1018–1025.
11. Said, Z.N.A., Abdelwahab, K.S., Induced immunity against hepatitis B virus. World J Hepatol 7:12 (2015), 1660–1670.
12. Petersen, K.M., Bulkow, L.R., McMahon, B.J., et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J. 23 (2004), 650–655.
13. Su, F.H., Cheng, S.H., Li, C.Y., Chen, J.D., Hsiao, C.Y., Chien, C.C., et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 25 (2007), 8085–8090.
14. Bruce, M.G., Bruden, D., Hurlburt, D., Zanis, C., Thompson, G., Rea, L., et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis 214:1 (2016), 16–22.
15. Mansour E, Abdul-Rahim S, Batouty G, Zaghloul I, Abdel-Hadi S. Integration of hepatitis B immunization in the Expanded Programon Immunization of the Child Survival Project. J Egypt Public Health Assoc 1993; 68:487–494 [PMID: 7775876].
16. Leuridan, E., Van Damme, P., Hepatitis B and the need for a booster dose. Clin Infect Dis 53:1 (2011), 68–75.
17. Baylis, S.A., Heath, A.B., Chudy, M., Pisani, G., Klotz, A., Kerby, S., et al. An international collaborative study to establish the 2nd World Health Organization International Standard for hepatitis B virus DNA nucleic acid amplification technology-based assays. Vox Sang 94 (2008), 358–362.
18. Chen YS, Chu CH, Wang JH, Lin JS, Chang YC. Predictors of booster response to hepatitis B vaccine at 15 years of age: a cross-sectional school-based study. Pediatr Neonatol 2016:57;302e309.
19. Ghalli I, Salah N, Hussein F, Erfan M, El Ruby M, Mazen I et al. Egyptian growth curves for infants, children and adolescents.Crecerenelmondo. In: Satorio A, Buckler JMH, Marazzi N., editors. Italy: Ferring Publisher; 2008.
20. Barlow, S.E., Expert committee recommendations regarding the prevention, assessment and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 120:Suppl 4 (2007), S164–S192.
21. Centers for Disease Control and Prevention (CDC).About BMI for children and teens. 2011; Available at: http://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens [Accessed 20 September 2017].
22. Zanetti A, Parlato A, Romanò L, Desole MG, Ferrera G, Giurdanella F et al. Challenge with a hepatitis B vaccine in two cohorts of 4–7-year-old children primed with hexavalent vaccines: an open-label, randomised trial in Italy. Vaccine 2012; 30: 5770-5775 [PMID: 22789511] http://doi.org/10.1016/j.vaccine.2012.06.078.
23. van der Sande, M.A., Waight, P.A., Mendy, M., Zaman, S., Kaye, S., Sam, O., et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One., 2(8), 2007, e753.
24. Shouval, D., Hepatitis B vaccines. J Hepatol 39 (2003), S70–S76.
25. World Health Organization. Media Center. Hepatitis B fact sheet; 2017 Available at: http://www.who.int/mediacentre/factsheets/fs204/en/ [Accessed 9 January 2018].
26. Williams, L.T., Goldstein, S.T., Tufa, J., Tauillii, S., Margolis, H.S., Mahoney, F.J., Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J 22 (2003), 157–163.
27. Hammitt, L.L., Hennessy, T.W., Fiore, A.E., Zanis, C., Hummel, K.B., Dunaway, E., et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 25 (2007), 6958–6964.
28. Lu, C.Y., Ni, Y.H., Chiang, B.L., Chen, P.J., Chang, M.H., Chang, L.Y., et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15–18 years after neonatal immunization. JID 197 (2008), 1419–1426.
29. Avdicova, M., Crasta, P.D., Hardt, K., Kovac, M., Lasting immune memory against hepatitis B following challenge 10–11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11–12 months of age. Vaccine 33 (2015), 2727–2733.
30. Kao, J.T., Wang, J.H., Hung, C.H., Yen, Y.H., Hung, S.F., Hu, T.H., et al. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine 27 (2009), 1858–1862.
31. Chang, Y.C., Wang, J.H., Chen, Y.S., Lin, J.S., Cheng, C.F., Chu, C.H., Hepatitis B virus vaccination booster does not provide additional protection in adolescents: a cross-sectional school-based study. BMC Public Health, 14, 2014, 991.
32. Wang, L.Y., Lin, H.H., Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago. Vaccine 25 (2007), 7160–7167.
33. Giambi, C., Bella, A., Barale, A., Montù, D., Marchisio, M., Oddone, M., et al. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. Infect Dis, 8, 2008, 100.
34. Samandari T, Fiore AE, Negus S, Williams JL, Kuhnert W, McMahon BJ et al. Differences in response to a hepatitis b vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007; 120; e373–e381; originally published online Jul 16, 2007.
35. Schillie, S.F., Murphy, T.V., Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. Vaccine. 31:21 (2013), 2506–2516.
36. Aypak, C., Yüce, A., Yıkılkan, H., Görpelioğlu, S., Persistence of protection of hepatitis B vaccine and response to booster immunization in 2- to12-year-old children. Eur J Pediatr 171:12 (2012 Dec), 1761–1766.
37. Zanetti, A.R., Romanò, L., Giambi, C., Pavan, A., Carnelli, V., Baitelli, G., et al. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis 10:11 (2010), 755–761.
38. Yazdanpanah, B., Safari, M., Yazdanpanah, S., Persistence of HBV vaccine's protection and response to hepatitis B booster immunization in 5- to 7-year-old children in the Kohgiloyeh and Boyerahmad Province, Iran. Hepat Mon 10:1 (2010), 17–21.
39. Koff, R.S., Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine 20:31–32 (2002), 3695–3701.
40. Zinke M, Kappes R, Kindler K, Paulus-Koschik A, Goering U, Disselhoff J et al. Immune memory to hepatitis B virus in 4–9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. HumVaccine 2009; 5:592–598.
41. Steiner, M., Ramakrishnan, G., Gartner, B., Meeren, O.V.D., Jeanne-Marie, J., Schuster, V., Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life. BMC Infecti Dis, 10, 2010, 9.
42. Zuckerman, J.N., Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 78:2 (2006 Feb), 169–177.